IVIG for Infection Prevention After CAR-T-Cell Therapy

NCT05952804 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Malignancies

Interventions

BIOLOGICAL: Immune Globulin Infusion (Human), 10% Solution
BIOLOGICAL: Anti-CD19 CAR T Cells Preparation
OTHER: Saline
PROCEDURE: Biospecimen Collection
OTHER: Survey Administration
OTHER: Electronic Health Record Review

Sponsor

Fred Hutchinson Cancer Center

Collaborators

[object Object]
[object Object]